Business
Interim results for six months ending 31/03/2026
IXICO plc reported a 23% increase in revenue to £3.9 million for the six months ending March 31, 2026, compared to £3.2 million in the prior year, with a gross margin rising to 53% from 50%. The company's order book grew by 38% to £18.1 million, and the EBITDA loss narrowed to £0.5 million from £0.7 million. Following the period, IXICO completed a £10 million capital raise to support its TechBio strategy, aiming to integrate its AI-driven platform with other industry providers. The company expects to be at least in line with market expectations for the full year 2026. Disclaimer*
About this update from Ixico Plc
[{"type":"text","content":"\n\nIXICO plc\n(\"IXICO\", the \"Company\" or the \"Group\")\nInterim results for six months ending 31 March 2026\nContinued strong revenue and order book growth\n \n19 May 2026 IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announces its unaudited interim results for the six months ended 31 March 2026 ('H1 2026' or 'the period').\n \nFinancial highlights\n· Revenues up 23% to £3.9 million (H1 2025: £3.2m), driven by new contract wins, contract extensions and an increased volume of analyses in H1 2026 relative to the equivalent prior period. The Company expects to be at least in line with market expectations for the full year 2026.\n \n· Gross margin increased to 53% (H1 2025: 50%).\n \n· Order book* of £18.1 million; an increase of 38% on 31 March 2025 (H1 2025: £13.1m) and 31% on 30 September 2025 (FY 2025: £13.8m).\n \n· Loss before interest, tax, depreciation and amortization of £0.5 million (H1 2025: £0.7m loss); reflecting increased revenues, offset by full period impact of investments made in the Company's Innovate, Lead, Scale strategy to deliver sustained revenue growth.\n \n· Cash position of £1.7 million (H1 2025: £5.0m).\n \n· The Group completed a capital raise of £10 million (£9.4 million after placing costs) after the period end, on 27 April 2026, to support its Tech Bio strategy - focussed on accessing novel revenue streams via integrating and partnering the IXITM platform within the wider ecosystem of CROs, clinical trial management and clinical healthcare providers.\n \n*Order book refers to those client contracts that have been signed by the Company but not yet delivered.\n \nCommercial & Operational highlights\n· Appointment of Tanya Voloshen as US-based Chief Commercial Officer.\n \n· Commercial agreement signed with Medidata (a Dassault Systèmes company), as a partnership where IXITM augments Medidata's well-established, clinical trials technology platform us...